HypOrth

Partner 6 - Progenika Biopharma

David Arteta

Progenika Biopharma
  

Dr. David Arteta

Project Leader

Phone: +34 94 4064525

Fax: +34 94 4064526

E-Mail

Progenika Biopharma S.A.

Parque Tecnológico de Zamudio, 504

48160 Derio

Spain

Website

Project Team

Dr Sergio Escorza

European Project Manager

Phone: +34 94 4064525

Fax: +34 94 4064526

E-Mail

Dr. Lourdes Osaba

Service Department Manager

Dr. Lourdes Palacios

Senior Scientist

Dr. Magdalena Szczypiorska

Researcher

Edurne Entrena

Technician
Progeneka Project Team

Company presentation

Progenika Biopharma S.A. is a Spanish biotechnology Grifols company specialized in the development of technology for personalized medicine. It focuses on the design and validation of genomic and proteomic tests for in vitro diagnostics, disease prognosis, drug therapy monitoring and prediction of response. Progenika has also developed proprietary technologies to produce molecular diagnostic and prognostic tests, and it is one of the most advanced companies in this field. In fact, Progenika is a worldwide pioneer in the development of molecular biology tests for transfusion compatibility studies.

Progenika´s R&D facilities are located in the Technological Park of Bizkaia, where the company holds 1000 m2 that comprise laboratories for functional genomics. In addition to the Affymetrix® GeneChip platform for high-throughput transcriptomic and genotyping systems, facilities include high-scale massive sequencing and expression quantification by RT-PCR. These technologies have been used to develop new diagnostic and prognostic products, of which some examples include: BLOODchip® reference, a solid array for the genotyping of human blood groups, the first extensive blood group genotyping test obtaining CE mark; IDCORE+®, IDCORE® and IDHPA®, liquid arrays (xMAP® technology) for the identification of RBC and HPAs antigens, respectively; or LIPONext®, for routine clinical diagnosis of Familial Hypercholesterolemia by detecting mutations involved in cardiovascular diseases using High-Scale Massive Sequencing. 

Personnel assigned to the project accumulate years of experience in functional genomics and transcriptomics, including several pipeline projects focused on chronic inflammatory diseases of the axial skeleton.

HypOrth Consortium

HypOrth Consortium
Home
Menu
Search
Top

Newsletter Subscription

News Section

Public poster session on September 1. Read more

Social Media

Twitter Google Plus Facebook
Home
Menu
Search
Top